Evidence map›Paper›PMID 28806079›Full record

ArticleJournal of medicinal chemistry2017

Pilot in Vivo Structure-Activity Relationship of Dihydromethysticin in Blocking 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone-Induced O

Manohar Puppala, Sreekanth C Narayanapillai, Pablo Leitzman, Haifeng Sun, Pramod Upadhyaya, M Gerard O'Sullivan, Stephen S Hecht, Chengguo Xing

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Natural Products Inhibition of Cytochrome P450 2B6 Activity and Methadone Metabolism.Drug metabolism and disposition: the biological fate of chemicals · 2024
    Article
  2. Opportunities and Challenges of Kava in Lung Cancer Prevention.International journal of molecular sciences · 2023
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Manohar PuppalaDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Sreekanth C NarayanapillaiDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Pablo LeitzmanDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Haifeng SunDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida , Gainesville, Florida 32610, United States.
Pramod UpadhyayaMasonic Cancer Center, University of Minnesota , Minneapolis, Minnesota 55455, United States.
M Gerard O'SullivanMasonic Cancer Center Comparative Pathology Shared Resource, University of Minnesota , St. Paul, Minnesota 55108, United States.
Stephen S HechtMasonic Cancer Center, University of Minnesota , Minneapolis, Minnesota 55455, United States.ORCID 0000-0001-7228-1356
Chengguo XingDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota , Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-4266-6236
University of Minnesota · USUniversity of Florida · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
Dihydromethysticin (DHM) for Lung Cancer ChemopreventionR01CA193278 · NCI · UNIVERSITY OF MINNESOTA · PI XING, CHENGGUO · 2015 to 2019
$1.7M
NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA193278
6 · The paper itself

Abstract

(+)-Dihydromethysticin was recently identified as a promising lung cancer chemopreventive agent, while (+)-dihydrokavain was completely ineffective. A pilot in vivo structure-activity relationship (SAR) was explored, evaluating the efficacy of its analogs in blocking 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced short-term O

Indexed as

AdenomaAnimalsAnticarcinogenic AgentsCarcinogensFemaleGuanineLungLung NeoplasmsMiceNitrosaminesPyronesStructure-Activity Relationship4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone7,8-dihydromethysticinAnticarcinogenic AgentsCarcinogensGuanineNitrosaminesO-(6)-methylguaninePyrones

Identifiers

PMID28806079
PMCPMC5729742
OpenAlexW2746790758

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.